Arrhythmia Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Arrhythmia treatment is the specialised management of abnormal heart rhythms — conditions in which the heart beats too fast (tachyarrhythmia), too slowly (bradyarrhythmia), or irregularly. Cardiac arrhythmias affect an estimated 1.5–5% of the general population and range from benign ectopic beats requiring no treatment to life-threatening ventricular fibrillation requiring immediate defibrillation. The treatment approach is determined by the arrhythmia mechanism (re-entry, automaticity, triggered activity), location (atrial or ventricular), haemodynamic significance, and underlying structural heart disease.

The foundational investigation is the 12-lead ECG during arrhythmia, supplemented by ambulatory monitoring (24-hour Holter, 7-day or 14-day patch monitors, or implantable loop recorders for infrequent events), exercise testing to reproduce exercise-induced arrhythmias, echocardiography to assess structural heart disease, and electrophysiology study for characterisation and ablation planning. Cardiac MRI may be indicated for suspected arrhythmogenic cardiomyopathy or to assess fibrosis and scar in patients with ventricular arrhythmias.

Treatment decisions balance the symptomatic burden of the arrhythmia against treatment risks. For benign arrhythmias — occasional ectopic beats, paroxysmal SVT in structurally normal hearts — reassurance and lifestyle modification may be sufficient, with pharmacological or ablative treatment reserved for those with significant symptoms. Life-threatening ventricular arrhythmias require aggressive evaluation, treatment of precipitating factors (ischaemia, electrolyte disturbance, medication toxicity), and definitive therapy with antiarrhythmic drugs, catheter ablation, and/or ICD implantation.

Atrial fibrillation (AF) — the most common sustained arrhythmia, affecting 40–50 million people globally — is treated with rate control, rhythm control, and anticoagulation for stroke prevention. Rate control (keeping the ventricular rate below 110 bpm at rest) uses beta-blockers, digoxin, and non-dihydropyridine calcium channel blockers (diltiazem, verapamil). Rhythm control (restoring and maintaining sinus rhythm) uses antiarrhythmic drugs (flecainide, propafenone, sotalol, amiodarone, dronedarone) or catheter ablation (pulmonary vein isolation).

Supraventricular tachycardias (SVT) — including AVNRT, accessory pathway tachycardias (WPW), atrial flutter, and focal atrial tachycardias — present with sudden-onset rapid regular palpitations and are treated acutely with vagal manoeuvres, adenosine, or cardioversion, and definitively with catheter ablation. Ventricular arrhythmias — ventricular premature contractions (VPCs), ventricular tachycardia (VT), and ventricular fibrillation (VF) — in structural heart disease require thorough evaluation and management combining antiarrhythmic drugs, catheter ablation, and ICD therapy. Bradyarrhythmias including sick sinus syndrome, AV block (first, second, and complete third degree), and bundle branch block require permanent pacemaker implantation when symptomatic.

Antiarrhythmic drug therapy is appropriate for patients with symptomatic arrhythmias when pharmacological management provides adequate symptom control with acceptable side effects, and for initial management of newly diagnosed arrhythmias. Catheter ablation is appropriate for patients with symptomatic arrhythmias where ablation offers a curative or high-success rate option, antiarrhythmic drug therapy has failed or is not tolerated, or the patient prefers a potentially curative procedure to indefinite medication. ICD implantation is indicated for secondary prevention (survivors of sudden cardiac arrest or haemodynamically significant VT without reversible cause) and primary prevention in patients with LVEF below 35% despite optimal medical therapy.

Patients with infrequent, well-tolerated, short-duration SVT episodes that terminate spontaneously and respond to Valsalva may choose watchful waiting without pharmacological treatment. Patients with asymptomatic ventricular ectopy and no structural heart disease generally require no treatment. High-risk WPW syndrome (short refractory period, history of pre-excited AF, syncope) requires urgent ablation regardless of symptoms. Electrolyte disturbances, thyrotoxicosis, medication toxicity, and reversible ischaemia as precipitants of arrhythmia must be identified and corrected before attributing arrhythmias to a fixed substrate requiring device therapy.

Antiarrhythmic drugs are classified by the Vaughan Williams classification: Class I agents block sodium channels (flecainide, propafenone — Class IC, for SVT and AF without structural heart disease; quinidine, disopyramide — Class IA); Class II agents are beta-blockers (metoprolol, bisoprolol, atenolol, carvedilol — rate control and anti-adrenergic effects); Class III agents block potassium channels to prolong action potential duration (sotalol — QT-prolonging, combined Class II/III; amiodarone — broad-spectrum, most effective but significant long-term toxicity profile; dronedarone — less effective than amiodarone but safer profile; dofetilide); Class IV agents are non-dihydropyridine calcium channel blockers (verapamil, diltiazem — for rate control in AF and SVT termination).

Cardioversion — restoration of sinus rhythm by delivering a synchronised DC electrical shock — is used for haemodynamically unstable arrhythmias (immediate cardioversion) or elective restoration of sinus rhythm in AF/flutter (pharmacological cardioversion with flecainide or ibutilide, or electrical cardioversion with transoesophageal echocardiography to exclude left atrial thrombus if AF duration exceeds 48 hours). Catheter ablation using radiofrequency (heat) or cryothermy (freeze) eliminates arrhythmia substrates percutaneously — it is curative for accessory pathways, AVNRT, atrial flutter, and focal atrial tachycardias, and increasingly effective for AF and VT. Pulsed field ablation (PFA) delivers high-voltage ultra-short electrical pulses that cause irreversible electroporation of cardiomyocytes with minimal thermal damage to adjacent structures, offering a safer modality for accessory pathways, AVNRT, atrial flutter, focal atrial tachycardias, and increasingly effective for AF and VT.

Catheter ablation for typical AVNRT or accessory pathway tachycardia achieves a cure rate of 95–97% with very low recurrence rates and minimal risk in experienced hands, effectively curing patients who may otherwise require lifelong antiarrhythmic medication. Typical atrial flutter ablation achieves 95% freedom from flutter with the cavotricuspid isthmus ablation approach. AF ablation (pulmonary vein isolation) achieves single-procedure freedom from AF in 70–80% of paroxysmal AF patients and 50–65% with persistent AF at 12 months.

Antiarrhythmic drug therapy provides effective symptom control in 50–70% of patients, with amiodarone being the most efficacious but with significant long-term organ toxicities. Rate control in AF with beta-blockers or digoxin achieves adequate ventricular rate control in over 80% of patients. ICD therapy reduces sudden cardiac death risk by 23–31% in primary prevention patients with reduced LVEF (SCD-HeFT: hazard ratio 0.77; MADIT-II: hazard ratio 0.69) and by 20–25% in secondary prevention. For VT ablation in structural heart disease, substrate-based mapping achieves freedom from VT in 50–70% of patients and eliminates VT storm in over 80% of cases.

Antiarrhythmic drugs carry significant arrhythmogenic risk — paradoxically, they can cause new or worsened arrhythmias in a proportion of patients. Class I antiarrhythmic drugs are contraindicated in structural heart disease (post-MI, reduced LVEF) due to increased mortality (CAST trial). Amiodarone causes thyroid dysfunction (hypo- or hyperthyroidism) in 15–20% of patients, pulmonary toxicity in 2–5% (potentially life-threatening), hepatotoxicity, corneal microdeposits (virtually universal), and peripheral neuropathy with long-term use. QT-prolonging drugs (sotalol, dofetilide, quinidine) can cause torsades de pointes — a potentially life-threatening polymorphic VT — requiring QT monitoring and dose adjustment.

Catheter ablation complications are procedure-specific and described in the cardiac mapping section. ICD complications include inappropriate shocks (10–20% of patients per year with older programming, reduced to below 5% with modern algorithms), device pocket haematoma, lead displacement (1–3%), and device infection (0.5–1%). PTSD and psychological distress following ICD shocks affect 10–20% of recipients and require psychological support.

Following antiarrhythmic drug initiation, monitoring for proarrhythmic effects (particularly QT prolongation with sotalol and dofetilide — initiation should be done in a monitored hospital setting) is essential. Organ function monitoring is required during long-term amiodarone therapy: thyroid function (every 6 months), liver function (annually), pulmonary function tests and chest X-ray (annually), ophthalmology review (annually), and nerve conduction studies if neuropathy is suspected.

Post-ablation follow-up involves ambulatory cardiac monitoring at 3, 6, and 12 months to assess arrhythmia recurrence, with a 3-month blanking period (during which early recurrences do not necessarily represent ablation failure) after AF ablation. Post-ICD implantation clinic follow-up at 6 weeks, 6 months, and annually assesses device function, lead parameters, battery longevity, and stored arrhythmia episodes. Remote monitoring — automatic transmission of device events via wireless home transmitters — has reduced clinic visit frequency while maintaining surveillance quality.

Antiarrhythmic drug therapy costs vary by agent — generic amiodarone or beta-blockers are inexpensive ($20–$100/month); newer branded agents like dronedarone cost $200–$400/month in the US. Long-term monitoring requirements (ECG, bloods, spirometry) add ongoing costs. Catheter ablation for AF in the US costs $25,000–$50,000 per procedure; SVT ablation $15,000–$25,000; VT ablation $30,000–$60,000. ICD implantation costs $35,000–$80,000. In the UK, these are provided free on the NHS for eligible patients.

For medical tourists, catheter ablation for AF at leading Indian EP centres costs $5,000–$10,000; SVT ablation $3,000–$6,000; ICD implantation $8,000–$20,000. These centres use the same CARTO/EnSite mapping technology and internationally branded devices as Western centres. Thailand, Turkey, and Singapore offer intermediate pricing. Short-term monitoring and follow-up after procedures are well-managed at specialist international centres with telemedicine follow-up facilitating international care coordination.

For patients with AF who prefer to avoid pharmacological therapy or catheter ablation, rate control strategy (accepting AF but controlling the ventricular rate) combined with anticoagulation for stroke prevention is a clinically valid long-term strategy, as established by the AFFIRM trial. The recent EAST-AFNET 4 trial demonstrated benefit of early rhythm control, but for patients with minimal AF symptoms and well-controlled rates, watchful rate control with anticoagulation remains appropriate.

For bradyarrhythmia management in emergency situations, transcutaneous pacing and atropine provide temporary support before permanent pacemaker implantation. For patients with supraventricular tachycardias who decline ablation, rate-limiting antiarrhythmic drugs (beta-blockers, verapamil, diltiazem) or pill-in-the-pocket flecainide taken at the onset of paroxysmal SVT provide effective symptom control without ongoing daily medication. Lifestyle modifications — reducing caffeine, alcohol, and stimulants; managing sleep apnoea (a major trigger for AF and SVT); and regular aerobic exercise — can significantly reduce arrhythmia burden and should be recommended to all arrhythmia patients.